Overview of the coagulation system

Indian Journal of Anaesthesia

Volumn 58, Issue 5, 2014, Pages 515-523

  Palta, Sanjeev ^a   Saroa, Richa ^a   Palta, Anshu ^a  

^a GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Anaesthesia; Coagulation system; Haemostasis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; FATTY ACID BINDING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; FIBRINOGEN DEFECT; FIBRINOLYSIS; HEMOPHILIA; HEMOSTASIS; LIVER DISEASE; PERIOPERATIVE PERIOD; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84924956744     PISSN: 00195049     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5049.144643     Document Type: Review

References (42)

1. Achneck HE, Sileshi B, Parikh A, Milano CA, Welsby IJ, Lawson JH. Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. Circulation 2010;122:2068-77.
2. Thornton P, Douglas J. Coagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol 2010;24:339-52.
3. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus 2011;9:120-38.
4. Bombeli T, Spahn DR. Updates in perioperative coagulation: Physiology and management of thromboembolism and haemorrhage. Br J Anaesth 2004;93:275-87.
5. Meybohm P, Zacharowski K, Weber CF. Point-of-care coagulation management in intensive care medicine. Crit Care 2013;17:218.
6. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-61.
7. Lasne D, Jude B, Susen S. From normal to pathological hemostasis. Can J Anesth 2006;53:S2-11.
8. Triplett DA. Coagulation and bleeding disorders: Review and update. Clin Chem 2000;46:1260-9.
9. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002;88:186-93.
10. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004;114:447-53.
11. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Hematol Oncol Clin North Am 1990;4:1-26.
12. Yenicesu I, Yetgin S, Ozyürek E, Aslan D. Virus-associated immune thrombocytopenic purpura in childhood. Pediatr Hematol Oncol 2002;19:433-7.
13. Colvin BT. Physiology of haemostasis. Vox Sang 2004;87 Suppl 1:43-6.
14. thed.New York NY: McGraw-Hill Professional Publishing; 2010. p. 614-6.
15. thed. Philadelphia: Elsevier Health Sciences; 2010. p. 457-9.
16. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424.
17. thed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 224-6.
18. Doolittle RF, Spraggon G, Everse SJ. Three-dimensional structural studies on fragments of fibrinogen and fibrin. Curr Opin Struct Biol 1998;8:792-8.
19. Kamath S, Lip GY. Fibrinogen: Biochemistry, epidemiology and determinants. QJM 2003;96:711-29.
20. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007;27:1687-93.
21. Manly DA, Boles J, Mackman N. Role of tissue factor in venous thrombosis. Annu Rev Physiol 2011;73:515-25.
22. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003;38:1075-89.
23. Closse C, Seigneur M, Renard M, Pruvost A, Dumain P, Belloc F, et al. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. Thromb Res 1997;85:159-64.
24. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002;30:S325-31.
25. Ejiofor JA. Anticlotting mechanisms I: Physiology and pathology. Contin Educ Anesth Crit Care Pain 2013;13:87-92.
26. Price GC, Thompson SA, Kam PC. Tissue factor and tissue factor pathway inhibitor. Anaesthesia 2004;59:483-92.
27. Dahm AE, Sandset PM, Rosendaal FR. The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. J Thromb Haemost 2008;6:393-5.
28. Rigby AC, Grant MA. Protein S: A conduit between anticoagulation and inflammation. Crit Care Med 2004;32:S336-41.
29. Corral J, Gonzalez-Conejero R, Hernandez-Espinosa D, Vicente V. Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol 2007;137:99-108.
30. rd, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost 2010;104:432-9.
31. thed. Philadelphia, PA: Saunders Elsevier; 2010. p. 118-20.
32. Martlew VJ. Peri-operative management of patients with coagulation disorders. Br J Anaesth 2000;85:446-55.
33. Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001;114:249-57.
34. Polderman HK. Hypothermia and coagulation. Crit Care 2012;16:A20.
35. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program 2013;2013:464-70.
36. Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol 2006;60:144-51.
37. Coppola R, Mari D, Lattuada A, Franceschi C. Von Willebrand factor in Italian centenarians. Haematologica 2003;88:39-43.
38. Pinjala RK, Reddy LR, Nihar RP, Praveen GV, Sandeep M. Thrombophilia - How far and how much to investigate? Indian J Surg 2012;74:157-62.
39. Martinelli I, Bucciarelli P, Mannucci PM. Thrombotic risk factors: Basic pathophysiology. Crit Care Med 2010;38:S3-9.
40. Jagneaux T, Taylor DE, Kantrow SP. Coagulation in sepsis. Am J Med Sci 2004;328:196-204.
41. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005;129:307-21.
42. Schuster V, Hügle B, Tefs K. Plasminogen deficiency. J Thromb Haemost 2007;5:2315-22.